SCHEMBL18067751

SCHEMBL18067751

CC(=O)OCC1O[C@@H](O[C@@H]2C3CO[C@H](O3)C3O[C@@H]32)[C@@H](OC(C)=O)C(C)[C@@H]1C

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ LMNA P02545 1/20 0.37
▸ NR3C1 P04150 1/20 0.36
▸ FYN P06241 1/20 0.36
▸ ADRA2A P08913 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.36
▸ ADRA2B P18089 1/20 0.36
▸ DRD4 P21917 1/20 0.36
▸ DRD3 P35462 1/20 0.36
▸ PRKCA P17252 1/20 0.36
▸ AKT1 P31749 1/20 0.36
▸ PTK2 Q05397 1/20 0.36
▸ TSHR P16473 1/20 0.34
▸ CA2 P00918 11/20 0.34
▸ CA12 O43570 10/20 0.34
▸ CA1 P00915 10/20 0.34
▸ CA9 Q16790 10/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18067731 1.00 CYP2D6 (0.39) CYP2D6THRBHSD17B10LMNANR3C1
SCHEMBL20990897 0.89 CYP2D6 (0.51) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL16731393 0.89 CYP2D6 (0.51) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL18045633 0.89 CYP2D6 (0.51) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL20990756 0.87 CYP2D6 (0.41) CYP2D6THRBHSD17B10LMNANR3C1
SCHEMBL18083469 0.84 CYP2D6 (0.36) CYP2D6THRBHSD17B10LMNANR3C1
SCHEMBL17805887 0.77 CYP2D6 (0.50) CYP2D6THRBHSD17B10LMNANR3C1
SCHEMBL19036045 0.77 CYP2D6 (0.50) CYP2D6THRBHSD17B10LMNANR3C1
SCHEMBL12136501 0.77 CYP2D6 (0.50) CYP2D6THRBHSD17B10LMNANR3C1
SCHEMBL18272663 0.77 CYP2D6 (0.50) CYP2D6THRBHSD17B10LMNANR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264609-A1 DISACCHARIDE INTERMEDIATE AND SYNTHESIS METHOD THEREOF ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2016-09-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264609-A1 DISACCHARIDE INTERMEDIATE AND SYNTHESIS METHOD THEREOF SI, FUT5, HPSE CYP2D6 425/4885THRB 4207/4885HSD17B10 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback